Linked Life Data

20035122

Source:http://linkedlifedata.com/resource/pubmed/id/20035122

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-12-25
pubmed:abstractText
Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is a recently developed liver-specific contrast agent for magnetic resonance (MR) imaging that is excreted equally via the kidneys and the biliary system. To our knowledge, its effects on T(2)-weighted MR cholangiopancreatography (MRCP) images have not been explored. Acquisition of the hepatobiliary phase is recommended 20 min after administration of Gd-EOB-DTPA. Examination time cannot be extended if the contrast does not take effect on T(2)-weighted MRCP within 20 min after administration. We attempted to assess the change in signal of T(2)-weighted MRCP by excretion of Gd-EOB-DTPA.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1880-2206
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
143-8
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Effects of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid on T2-weighted MRCP.
pubmed:affiliation
Department of Radiology, Kure City Medical Association Hospital, Kure, Hiroshima, Japan. yukon@kure-nh.go.jp
pubmed:publicationType
Journal Article